NAD+: The Cell's Energy Currency and Its Age-Related Decline

The short version

NAD+ stands for Nicotinamide Adenine Dinucleotide. It has been in biochemistry textbooks for a century as the cell's central electron carrier — the molecule that shuttles energy through glycolysis and the mitochondria to make ATP. What shifted scientific attention toward aging was the discovery that NAD+ also gets consumed by signaling enzymes — sirtuins, PARPs, CD38 — that govern DNA repair, gene expression, and inflammation, and that tissue NAD+ levels decline measurably as we age, partly because the NAD-consuming enzyme CD38 rises with age and chronic inflammation ^[4].

This has generated a decade of clinical testing with precursors — primarily NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — that the body converts to NAD+. Human trials have consistently raised blood NAD+. Translation to hard clinical endpoints such as longevity or disease prevention is less settled: a 2025 review in Nature Metabolism concluded that human efficacy data remain limited and tissue-specific NAD+ dynamics are still sparse ^[1]. This page summarizes what the clinical literature actually shows. No dose or regimen is recommended here.

What it is

NAD+ is a dinucleotide: nicotinamide mononucleotide and adenosine monophosphate joined by two bridging phosphate groups. The nicotinamide ring accepts and donates electrons, cycling between the oxidized form (NAD+) and the reduced form (NADH). Molecular formula C₂₁H₂₇N₇O₁₄P₂.

Its status is worth stating precisely: NAD+ and its precursors (NMN, NR, nicotinamide) are sold as dietary supplements; they are not FDA-approved drugs. The regulatory footing is more complicated than a single label captures — the FDA has taken the position that NMN may be excluded from the dietary supplement definition because of prior drug investigation, creating real marketplace uncertainty ^[4]. Compounded injectable NAD+ exists in wellness IV clinics but is not an approved pharmaceutical and has been subject to a Class I recall for endotoxin contamination. None of this changes the underlying research interest; it does shape how the evidence should be weighed.

How it works

NAD+ plays two distinct roles in the cell that are worth keeping separate.

First, it is a redox carrier. In glycolysis and the TCA cycle, enzymes strip electrons from fuel molecules and load them onto NAD+, forming NADH. NADH then carries those electrons to the mitochondrial electron-transport chain, where they drive the synthesis of ATP. This role is ancient, universal, and not controversial.

Second, NAD+ is a consumed signaling substrate. The sirtuin family of deacylases (SIRT1 through SIRT7) uses NAD+ as a co-substrate to remove chemical modifications from histone and non-histone proteins, regulating gene expression, mitochondrial biogenesis, and stress responses. PARP1, the primary DNA-damage response enzyme, uses NAD+ to build poly(ADP-ribose) chains at break sites. CD38 and CD157 are ectoenzymes on immune and other cells that also consume NAD+, and both rise with age and inflammation ^[4].

The aging-research hypothesis is that age-related NAD+ decline — driven partly by rising CD38 — reduces sirtuin and PARP activity, impairs DNA repair and mitochondrial maintenance, and contributes to the metabolic dysfunction of aging. Restoring NAD+ with precursors is the proposed remedy; how much of that remedy translates from rodents to humans is the live question.

What the research shows

The 2025 human evidence synthesis. A 2025 narrative review in Nature Metabolism evaluated the totality of human clinical evidence on NAD+ precursor supplementation in aging. Its conclusions are worth quoting carefully: human trials have shown limited efficacy; age-related NAD+ decline has been observed consistently only in a limited number of human studies; tissue-specific NAD+ dynamics remain sparse; and the field needs more clinical studies of systemic and tissue-specific NAD+ metabolism rather than reliance on rodent extrapolation ^[1].

NMN multicenter RCT. A multicenter double-blind placebo-controlled trial in healthy middle-aged adults tested oral NMN at three doses for 60 days. Blood NAD+ rose dose-dependently at days 30 and 60 across all NMN groups versus placebo (p≤0.001); walking distance and quality-of-life scores improved; 600 mg/day was identified as the optimal dose; no safety signals emerged at any dose ^[2].

NMN and insulin sensitivity. Ten weeks of oral NMN supplementation improved skeletal muscle insulin sensitivity — assessed by hyperinsulinemic-euglycemic clamp, the gold-standard measure — and remodeled insulin signaling in prediabetic, postmenopausal women. Body composition and HbA1c did not change, which the authors note suggests NMN's action is specific to muscle insulin signaling rather than systemic glucose metabolism ^[3].

NR dose-escalation safety. A randomized, double-blind, placebo-controlled trial of NR (nicotinamide riboside chloride, sold as NIAGEN) at 100, 300, and 1000 mg/day for 8 weeks in healthy overweight adults found dose-dependent whole-blood NAD+ increases of 22%, 51%, and 142% respectively, no flushing at any dose (distinguishing it from plain niacin), and no significant adverse-event differences from placebo ^[5].

Mechanistic framework. The foundational review establishing the rationale identifies the major NAD-consuming enzymes — sirtuins SIRT1-7, PARP1, and CD38/CD157 — and frames the age-related competition for a declining NAD+ pool as a candidate driver of metabolic dysfunction and disease susceptibility across model organisms and humans ^[4].

Reported effects, cautions & safety

The following cautions follow directly from the published literature:

• Oral NAD+ itself is not the effective supplement form. NAD+ as a molecule is poorly taken up by cells intact; most experts consider precursors (NMN, NR) the rational oral approach, and there is a reasonable argument that plain "NAD+" capsules are largely ineffective at raising intracellular NAD+ ^[4].
• Raising blood NAD+ is not the same as clinical benefit. Every precursor trial has raised blood NAD+ reliably; translation to hard endpoints — longevity, cardiovascular outcomes, cognitive preservation — in humans remains undemonstrated ^[1].
• Rodent-to-human extrapolation is a known risk. The most dramatic anti-aging data come from mice; the 2025 review explicitly cautions against assuming these findings translate ^[1].
• IV NAD+ carries specific risks. Infused NAD+ is rapidly cleared from plasma; infusions can cause chest discomfort, flushing, and nausea if administered too quickly. Compounded injectable NAD+ has been subject to a Class I recall for elevated bacterial endotoxin ^[4].
• Theoretical oncology concern. NAD+ supports proliferating cells; a theoretical concern exists that boosting NAD+ could support the metabolism of pre-existing cancers. NAD+ has context-dependent dual roles in oncology, and caution is advised in cancer populations ^[4].
• NMN regulatory uncertainty. The FDA's position that NMN may not qualify as a dietary supplement creates marketplace risk for consumers and uncertainty about product legality ^[4].
• Supplement quality is unguaranteed. Products vary widely in actual content and purity; third-party testing is not universally required or applied.

Where it fits in longevity research

NAD+ occupies a curious position in this desk's landscape. Of the two molecules covered here, it is the one with the most direct human clinical evidence — actual randomized controlled trials in humans, with blood NAD+ as a verified biomarker and some functional endpoints ^[2][3][5]. It is also the one where the gap between what is demonstrated (blood NAD+ rises) and what is claimed (anti-aging, disease prevention, performance) is the widest. The 2025 synthesis ^[1] does not dismiss the research program; it characterizes it accurately as a field that has found a reliable biomarker and is still building toward clinical outcomes.

Read alongside MOTS-c, NAD+ illustrates how different two longevity-relevant molecules can be: one approaches aging at the level of fuel and signaling chemistry, the other through a retrograde communication channel between the mitochondria and the nucleus. See both on the comparison page.